GGrantIndex
← Leaderboards

Dung T Le

Johns Hopkins University

$5,608,820
Attributed
$5,608,820
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $669.4K · FY201225
$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,008,820 · 2
FDA$1,600,000 · 1

By mechanism

P01$3,293,864 · 1
R01$1,600,000 · 1
K23$714,956 · 1

Top collaborators

No co-investigators on record.

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Randomized

Research focus

RandomizedTumor ImmunityImmunotherapyPreclinical StudyT Cell ResponseTumor AntigensGranulocyte-Macrophage Colony-Stimulating FactorImmunotherapeutic AgentPancreatic Ductal AdenocarcinomaPeripheral BloodResponseSignal TransductionT-LymphocyteTumorCellsChemokineImmuneImmune ResponseListeria MonocytogenesMesothelinCancer TypePathway InteractionsAllogenicVaccines

Grant awards (13)

A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity$669,436
P01 · FY2025 · CA · contact PI
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity$635,965
P01 · FY2024 · CA · contact PI
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity$656,048
P01 · FY2023 · CA · contact PI
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity$662,979
P01 · FY2022 · CA · contact PI
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity$669,436
P01 · FY2021 · CA · contact PI
Phase 2 Study of Folfirinox Followed by Ipilimumab/GVAX in Pancreatic Cancer$400,000
R01 · FY2017 · FD · contact PI
Phase 2 Study of Folfirinox Followed by Ipilimumab/GVAX in Pancreatic Cancer$400,000
R01 · FY2016 · FD · contact PI
Phase 2 Study of Folfirinox Followed by Ipilimumab/GVAX in Pancreatic Cancer$400,000
R01 · FY2015 · FD · contact PI
Cyclophosphamide modified GM-CSF pancreatic tumor vaccine + listeria-mesothelin$178,739
K23 · FY2015 · CA · contact PI
Phase 2 Study of Folfirinox Followed by Ipilimumab/GVAX in Pancreatic Cancer$400,000
R01 · FY2014 · FD · contact PI
Cyclophosphamide modified GM-CSF pancreatic tumor vaccine + listeria-mesothelin$178,739
K23 · FY2014 · CA · contact PI
Cyclophosphamide modified GM-CSF pancreatic tumor vaccine + listeria-mesothelin$178,739
K23 · FY2013 · CA · contact PI
Cyclophosphamide modified GM-CSF pancreatic tumor vaccine + listeria-mesothelin$178,739
K23 · FY2012 · CA · contact PI